Morepen proposes dividend after 23 years as FY25 profit surges
Morepen Laboratories manufactures APIs, branded and generic formulations and home health products. The board has proposed a dividend of ₹0.20 per share after 23 years, pending shareholder approval at AGM. This follows strong FY25 results, with gross revenue increasing by 7.4% to ₹1,830 crore. EBITDA rose 11.5% to ₹192 crore and PAT surged to ₹118 crore with EPS climbing 17%.